UBS Cuts Price Target on Celyad SA (CYAD) to $79 Following 1H15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Celyad Reports First Half 2015 Financial Results and Operational Progress
August 25, 2015 1:04 AM EDTMONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the company's statutory auditors.
OPERATIONAL HIGHLIGHTS
Clinical... MoreCelyad Reports First Half 2015 Financial Results and Operational Progress
August 25, 2015 1:04 AM EDTMONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the company's statutory auditors.
OPERATIONAL HIGHLIGHTS
Clinical... MoreCelyad Reports First Half 2015 Financial Results and Operational Progress
August 25, 2015 1:00 AM EDTMONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD) (Paris: CYAD) (Brussels: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the companys statutory auditors.
... More
